Sekisui Diagnostics’ Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing $1.9 million, is part of a long-term investment strategy to grow its share of the Microbial Biopharma CDMO market, with future investment expected to focus on expanding its cGMP manufacturing capabilities, starting with additional ISO 8 clean room capacity coming online by the end of 2019.
“This investment represents our commitment to serve our customers with innovative process development solutions,” said Will Stockburn, Sekisui Diagnostics (UK) Ltd.’s General Manager. “Over many years we have built a technical competency in enzyme production process development. The new facility will enable our team to attract more customers as the Biopharma CDMO market grows.”